Host-Directed FDA-Approved Drugs with Antiviral Activity Against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods

    April 2021 in “ Pharmaceuticals ”
    Tiziana Ginex, Urtzi Garaigorta, David Ramírez … Carmen Gil
    Studysummary This study identified five FDA-approved drugs—cepharantine, clofazimine, metergoline, imatinib, and efloxate—as potential candidates for repurposing to interfere with viral entry in COVID-19 treatment.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on mdpi.com →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Cepharanthine: A Review of the Antiviral Potential of a Japanese-Approved Alopecia Drug in COVID-19 Pharmacological Reports · 2020